Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Novavax Inc

Healthcare US NVAX

10.69USD
0.14(1.33%)

Last update at 2026-03-10T20:26:00Z

Day Range

10.4410.82
LowHigh

52 Week Range

3.5323.86
LowHigh

Fundamentals

  • Previous Close 10.55
  • Market Cap1411.23M
  • Volume3583276
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-243.24600M
  • Revenue TTM885.19M
  • Revenue Per Share TTM6.19
  • Gross Profit TTM 115.46M
  • Diluted EPS TTM-2.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -653.64700M -1714.53600M -418.25900M -132.69400M -184.74800M
Minority interest - - - - -
Net income -657.93900M -1743.75100M -427.50500M -130.10200M -184.74800M
Selling general administrative 488.69M 298.36M 145.29M 34.42M 34.41M
Selling and marketing expenses - - - - -
Gross profit 696.31M 1146.29M 475.60M 18.66M 34.29M
Reconciled depreciation 29.05M 12.66M 4.88M 5.68M 8.16M
Ebit -644.73600M -1699.23700M -421.60400M -120.58100M -182.07700M
Ebitda -633.76700M -1686.57600M -416.71900M -138.61300M -173.91800M
Depreciation and amortization 10.97M 12.66M 4.88M -18.03200M 8.16M
Non operating income net other - -6.83300M 13.61M 1.50M 2.78M
Operating income -644.73600M -1686.57600M -416.71900M -120.58100M -173.91800M
Other operating expenses 2243.69M 2832.87M 892.32M 148.26M 208.21M
Interest expense 19.88M 21.13M 15.14M 12.19M 12.19M
Tax provision 4.29M 29.21M - - -
Interest income - - - 12.10M 10.94M
Net interest income -19.88000M -21.12700M -15.14500M -13.61200M -13.61200M
Extraordinary items - - - - -
Non recurring - - - -9.01600M -
Other items - - - - -
Income tax expense 4.29M 29.21M 9.25M -2.59200M 1.36M
Total revenue 1598.95M 1146.29M 475.60M 18.66M 34.29M
Total operating expenses 1341.05M 2832.87M 892.32M 148.26M 208.21M
Cost of revenue 902.64M - - 113.84M 173.80M
Total other income expense net -8.91100M -27.96000M -1.54000M -12.11300M 0.11M
Discontinued operations - - - - -
Net income from continuing ops -657.93900M -1743.75100M -418.25900M -132.69400M -184.74800M
Net income applicable to common shares -657.93900M -1743.75100M -418.25900M -132.69400M -184.74800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1855.34M 2258.68M 2576.75M 1582.48M 172.96M
Intangible assets - - 4.77M 5.72M 5.58M
Earning assets - - - - -
Other current assets 226.02M 1691.43M 2141.98M 441.82M 93.89M
Total liab 2572.27M 2892.76M 2928.43M 955.27M 358.97M
Total stockholder equity -716.92700M -634.07800M -351.67300M 627.21M -186.01700M
Deferred long term liab - - - - 2.50M
Other current liab 1233.10M 1521.21M 709.79M -327.56000M 19.95M
Common stock 1.41M 0.87M 0.76M 0.71M 0.32M
Capital stock 1.41M 0.87M 0.76M 0.71M 0.32M
Retained earnings -4820.95100M -4275.88900M -3617.95000M -1874.19900M -1431.80100M
Other liab - 185.02M 175.53M 3.36M 2.56M
Good will 127.45M 126.33M 131.48M 135.38M 51.15M
Other assets - 28.47M 16.57M 5.42M 1.08M
Cash 578.93M 1336.88M 1515.12M 553.40M 78.82M
Cash and equivalents - - - - -
Total current liabilities 1635.14M 2459.94M 2390.32M 322.04M 25.80M
Current deferred revenue 241.31M 370.14M 1422.94M 273.23M 1.68M
Net debt -298.29400M -787.10200M -1061.12500M -231.36300M 243.05M
Short term debt 28.12M 352.08M 130.53M 322.04M 1.26M
Short long term debt - 324.88M - 322.04M -
Short long term debt total 280.63M 549.78M 453.99M 322.04M 321.87M
Other stockholder equity 4099.90M 3647.32M 3266.87M 2493.67M 1257.97M
Property plant equipment - 400.49M 228.70M 179.95M 11.45M
Total current assets 1143.89M 1703.39M 2155.12M 1248.20M 97.25M
Long term investments - - - - -
Net tangible assets - -760.40900M -487.92200M 486.11M -242.75200M
Short term investments - - 0.00000M 157.65M 0.00000M
Net receivables 297.24M 82.38M 454.99M 262.01M 7.50M
Long term debt 168.02M 166.47M 323.46M 322.04M 320.61M
Inventory 41.70M 36.68M -1956.96600M -166.67200M -82.96600M
Accounts payable 132.61M 216.52M 127.05M 54.33M 2.91M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.72M -6.37700M -1.35300M 7.02M -12.50800M
Additional paid in capital - - - - -
Common stock total equity - - 0.76M 0.71M 0.32M
Preferred stock total equity - - - - -
Retained earnings total equity - - -3617.95000M -1874.19900M -1431.80100M
Treasury stock - - -85.10100M -41.80600M -2.58300M
Accumulated amortization - - - - -
Non currrent assets other 30.28M 28.47M 56.69M 13.22M 7.53M
Deferred long term asset charges - - - - -
Non current assets total 711.45M 555.29M 421.63M 334.28M 75.71M
Capital lease obligations 61.06M 58.43M 130.53M 149.73M 1.26M
Long term debt total - - 323.46M 322.04M 320.61M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -92.98500M 157.64M -157.64000M 22.02M 29.97M
Change to liabilities -132.51500M 1925.88M 434.71M -19.81600M -22.35400M
Total cashflows from investing activities -92.98500M 100.15M -377.77800M 38.49M 28.60M
Net borrowings 81.66M -127.90700M -96.06500M -96.06500M -96.06500M
Total cash from financing activities 324.99M 461.71M 984.76M 98.38M 102.81M
Change to operating activities - - - -4.20200M 1.21M
Net income -657.93900M -1743.75100M -418.25900M -132.69400M -184.74800M
Change in cash -179.41400M 879.52M 566.56M 0.22M -53.47200M
Begin period cash flow 1528.26M 648.74M 82.18M 81.96M 135.43M
End period cash flow 1348.85M 1528.26M 648.74M 82.18M 81.96M
Total cash from operating activities -415.93700M 322.95M -42.54100M -136.62300M -184.82500M
Issuance of capital stock 249.23M 564.86M 1075.44M 97.39M 100.06M
Depreciation 29.05M 12.66M 4.88M 5.68M 8.16M
Other cashflows from investing activities - - -165.51600M 18.33M 18.33M
Dividends paid - - - - -
Change to inventory -477.80100M -600.32600M -163.16100M -8.87200M -
Change to account receivables 249.17M -192.26500M -422.68900M -4.20200M 1.21M
Sale purchase of stock - 589.62M 1119.91M 98.38M 102.81M
Other cashflows from financing activities 169.35M 24.76M 205.20M 0.99M 2.75M
Change to netincome 574.10M 175.99M 111.53M 12.99M 11.48M
Capital expenditures 92.98M 57.49M 54.62M 1.86M 1.37M
Change receivables - 144.43M 245.86M - -
Cash flows other operating - -192.26500M -422.68900M -4.20200M 1.21M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 884.81M 564.44M 0.25M -53.42400M
Change in working capital -361.15000M 1733.62M 12.02M -24.01800M -21.14200M
Stock based compensation 130.30M 183.63M 128.03M 17.05M 18.31M
Other non cash items 443.80M 136.79M 230.78M 6.29M -5.35300M
Free cash flow -508.92200M 265.46M -97.16300M -138.48000M -186.19700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NVAX
Novavax Inc		 0.14 1.33% 10.69 - 7.92 1.59 49.52 0.79 -0.534
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax Inc

700 Quince Orchard Road, Gaithersburg, MD, United States, 20878

Key Executives

Name Title Year Born
Mr. Stanley Charles Erck Pres, CEO & Director 1948
Mr. James Patrick Kelly C.F.A. Exec. VP, CFO & Treasurer 1966
Mr. John A. Herrmann III Exec. VP, Chief Legal Officer & Corp. Sec. 1966
Mr. John Joseph Trizzino B.S., M.B.A. Exec. VP and Chief Bus. & Commercial Officer 1960
Dr. Gregory M. Glenn Pres of R&D 1954
Mr. Richard P. Crowley Exec. VP & COO 1957
Dr. Gale E. Smith Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist 1950
Mr. Biegie Lee Sr. VP & Chief Information Officer NA
Mr. Troy Morgan Esq., J.D. Sr. VP & Chief Compliance Officer 1971
Ms. Erika S. Trahan Associate Director of Investor & PR NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.